Key takeaways
- Gilead Sciences increased its quarterly dividend by 3.8% this year.
- The dividend yield, at Gilead's current share price, is around 1.9%, nearly double the S&P 500 (^GSPC +1.58%) average.
- Gilead's cash dividend payout ratio is only 29.8%, indicating it has ample room to maintain its dividend and fund other operations.
Gilead's HIV therapies generate strong free cash flow. The company is successfully branching out into oncology and anti-inflammatory therapies.
See the latest quote, chart and news for GILD.
